Ravulizumab is a monoclonal antibody and C5 complement inhibitor used in the treatment of conditions such as paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. Analytical laboratories… Read more
Ravulizumab is a monoclonal antibody and C5 complement inhibitor used in the treatment of conditions such as paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. Analytical laboratories require high-quality reference standards to support the development and characterization of this complex therapeutic. This category includes essential materials such as synthetic peptide fragments and stable isotope labelled compounds, which are critical for the precise analytical testing and method validation of the drug. By utilizing these impurity standards, researchers can perform accurate impurity profiling and ensure consistency throughout the manufacturing process. These deuterated reference materials and peptide fragments serve as vital controls for verifying molecular structure and concentration, ultimately supporting the rigorous quality control protocols necessary for ensuring the safety and efficacy of monoclonal antibody therapeutics.